,

Introduction to Market Access for Pharmaceuticals

Paperback Engels 2017 1e druk 9781138032187
€ 199,97
Levertijd ± 11 werkdagen
Gratis verzonden

Samenvatting

Market access is the fourth hurdle in the drug development process and the primary driver for global income of any new drug. Without a strategy in place for pricing, showing value for effectiveness and an understanding of the target purchasers’ needs, the drug will fail to reach its intended market value. Introduction to Market Access for Pharmaceuticals is based on an accredited course in this area, taken from the European Market Access University Diploma (EMAUD), and is affiliated with Aix Marseille University.

Key Features:The first guide to market access for pharmaceuticals based on tested teaching materialsAddresses both pharmaceutical and vaccine productsIncludes case studies and scenariosCovers market access consdierations for Western Europe, the USA, Japan and ChinaExplains the impact the changing healthcare market will have on your product

Specificaties

ISBN13:9781138032187
Taal:Engels
Bindwijze:Paperback
Aantal pagina's:204
Uitgever:CRC Press
Druk:1

Lezersrecensies

Wees de eerste die een lezersrecensie schrijft!

Inhoudsopgave

Chapter 1: Health as a Good

Chapter 2: Decision-Making in Public Health

Chapter 3: Definition and Concepts

Chapter 4: HTA Decision Analysis framework

Chapter 5: Early HTA Advice

Chapter 6: Overview of Market Access Agreements

Chapter 7: External Reference Pricing

Chapter 8: Gap between Payers and Regulators

Chapter 9: Early Access Programs

Chapter 10: Market Access of Orphan Drugs

Chapter 11: Market Access of Vaccines in Developed Countries

Chapter 12: France

Chapter 13: Germany

Chapter 14: Italy

Chapter 15: Spain

Chapter 16: Sweden

Chapter 17: United Kingdom

Chapter 18: The United States

Chapter 19: Japan

Chapter 20: China

Managementboek Top 100

€ 199,97
Levertijd ongeveer 11 werkdagen
Gratis verzonden

Rubrieken

Producten

    Auteurs

      Trefwoorden

        Artikelen

          Introduction to Market Access for Pharmaceuticals